Lung cancer patients get a boost: own immune cells tested to stop return
NCT ID NCT07444437
First seen Mar 04, 2026 · Last updated Apr 24, 2026 · Updated 8 times
Summary
This study tests a new treatment using a patient's own immune cells (called TILs) to help control non-small cell lung cancer after surgery. About 45 people who have already had chemotherapy and surgery will be split into three groups to compare the TIL therapy against standard care. The goal is to see if the TILs can delay or prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.